Huang, J., Chen, A., Jin, H., Liu, F., Hei, G., Teng, Z., Xiao, J., Wu, R., Zhao, J., Davis, J. M., Shao, P., & Smith, R. C. (2025). Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/jcp.24m15272

Ray, W. A., Fuchs, D. C., Olfson, M., Stein, C. M., Murray, K. T., Daugherty, J., & Cooper, W. O. (2024). Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study. Journal of Child and Adolescent Psychopharmacology, 34(9), 397–406. https://doi.org/10.1089/cap.2024.0047

Harnisch, M., Barnett, M. L., Coussens, S., Thomas, K. S., Olfson, M., Berhane, K., & Sacarny, A. (2024). Physician Antipsychotic Overprescribing Letters and Cognitive, Behavioral, and Physical Health Outcomes Among People With Dementia. JAMA Network Open, 7(4), e247604. https://doi.org/10.1001/jamanetworkopen.2024.7604

Gao, Y. N., Wang, R., Gu, G., Chung, R., & Olfson, M. (2024). Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders. Schizophrenia Research, 267, 165–172. https://doi.org/10.1016/j.schres.2024.03.034

van der Pluijm, M., Wengler, K., Reijers, P. N., Cassidy, C. M., Tjong Tjin Joe, K., de Peuter, O. R., Horga, G., Booij, J., de Haan, L., & van de Giessen, E. (2024). Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia. American Journal of Psychiatry, 181(6), 512–519. https://doi.org/10.1176/appi.ajp.20220780

Ray, W. A., Fuchs, D. C., Olfson, M., Patrick, S. W., Stein, C. M., Murray, K. T., Daugherty, J., & Cooper, W. O. (2024). Antipsychotic Medications and Mortality in Children and Young Adults. JAMA Psychiatry, 81(3), 260. https://doi.org/10.1001/jamapsychiatry.2023.4573

Lawrence, R. E., & Bernstein, A. (2024). Schizophrenia and Emergency Medicine. Emergency Medicine Clinics of North America, 42(1), 93–104. https://doi.org/10.1016/j.emc.2023.06.012

Lawrence, R. E., & Appelbaum, P. S. (2024). Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks. Schizophrenia Research, 264, 372–377. https://doi.org/10.1016/j.schres.2024.01.018

Devanand, D. P. (2023). Management of neuropsychiatric symptoms in dementia. Current Opinion in Neurology, 36(5), 498–503. https://doi.org/10.1097/wco.0000000000001199

Yoshida, K., Marshe, V. S., Elsheikh, S. S. M., Maciukiewicz, M., Tiwari, A. K., Brandl, E. J., Lieberman, J. A., Meltzer, H. Y., Kennedy, J. L., & Müller, D. J. (2023). Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study. The Pharmacogenomics Journal, 23(5), 119–126. https://doi.org/10.1038/s41397-023-00305-y

First, M. B., Clarke, D. E., Yousif, L., Eng, A. M., Gogtay, N., & Appelbaum, P. S. (2023). DSM-5-TR: Rationale, Process, and Overview of Changes. Psychiatric Services, 74(8), 869–875. https://doi.org/10.1176/appi.ps.20220334

Sehatpour, P., Iosifescu, D. V., De Baun, H. M., Shope, C., Mayer, M. R., Gangwisch, J., Dias, E., Sobeih, T., Choo, T.-H., Wall, M. M., Medalia, A., Saperstein, A. M., Kegeles, L. S., Girgis, R. R., Carlson, M., & Kantrowitz, J. T. (2023). Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. Biological Psychiatry, 94(2), 164–173. https://doi.org/10.1016/j.biopsych.2023.01.015

Kantrowitz, J. T., Correll, C. U., Jain, R., & Cutler, A. J. (2023). New Developments in the Treatment of Schizophrenia: An Expert Roundtable. International Journal of Neuropsychopharmacology, 26(5), 322–330. https://doi.org/10.1093/ijnp/pyad011

Ivanov, I., Boedhoe, P. S. W., Abe, Y., Alonso, P., Ameis, S. H., Arnold, P. D., Balachander, S., Baker, J. T., Banaj, N., Bargalló, N., Batistuzzo, M. C., Benedetti, F., Beucke, J. C., Bollettini, I., Brem, S., Brennan, B. P., Buitelaar, J., Calvo, R., Cheng, Y., … Park, S. (2022). Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium. Journal of Affective Disorders, 318, 204–216. https://doi.org/10.1016/j.jad.2022.08.084

Gao, Y. N., & Olfson, M. (2022). National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era. Schizophrenia Research, 248, 320–328. https://doi.org/10.1016/j.schres.2022.09.023

Willems, A. E., Mentzel, C. L., Bakker, P. R., Van Os, J., Tenback, D. E., Gelan, P., Daantjes, E., Matroos, G. E., Hoek, H. W., & Van Harten, P. N. (2022). Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV. Schizophrenia Bulletin, 48(4), 766–773. https://doi.org/10.1093/schbul/sbac037

Nemani, K., Williams, S. Z., Olfson, M., Leckman-Westin, E., Finnerty, M., Kammer, J., Smith, T. E., Silverman, D. J., Lindenmayer, J.-P., Capichioni, G., Clelland, J., & Goff, D. C. (2022). Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System. JAMA Network Open, 5(5), e2210743. https://doi.org/10.1001/jamanetworkopen.2022.10743

Choo, T., Xu, Q., Budimirovic, D., Lozano, R., Esler, A. N., Frye, R. E., Andrews, H., & Velinov, M. (2022). Height and BMI in fragile X syndrome: A longitudinal assessment. Obesity, 30(3), 743–750. Portico. https://doi.org/10.1002/oby.23368

Soto-Martin, M., Foff, E. P., & Devanand, D. P. (2022). Relapse in Dementia-related Psychosis and Clinical Decisions. Alzheimer Disease & Associated Disorders, 36(2), 180–184. https://doi.org/10.1097/wad.0000000000000480

Persico, M., Abbruzzese, C., Matteoni, S., Matarrese, P., Campana, A. M., Villani, V., Pace, A., & Paggi, M. G. (2022). Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. Cells, 11(2), 263. https://doi.org/10.3390/cells11020263